Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 4/20 | 0.64 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4657446 | 0.93 | MVD (0.57) | MVDBTN3A1GGPS1CHRM2CHRM4 | |
| SCHEMBL11952584 | 0.86 | MVD (0.49) | MVDBTN3A1GGPS1CHRM2CHRM4 | |
| SCHEMBL1642999 | 0.82 | LPAR3 (0.46) | MVDGGPS1CHRM2CHRM4CHRM5 | |
| SCHEMBL8232301 | 0.81 | MVD (0.43) | MVDBTN3A1GGPS1CHRM2CHRM4 | |
| SCHEMBL7531145 | 0.79 | BTN3A1 (0.61) | MVDBTN3A1GGPS1FNTAFNTB | |
| SCHEMBL2628074 | 0.79 | MVD (0.42) | MVDBTN3A1GGPS1CHRM2CHRM4 | |
| SCHEMBL2471602 | 0.79 | MVD (0.42) | MVDBTN3A1GGPS1CHRM2CHRM4 | |
| SCHEMBL14750297 | 0.79 | MVD (0.42) | MVDBTN3A1GGPS1CHRM2CHRM4 | |
| SCHEMBL27703224 | 0.78 | MVD (0.41) | MVDBTN3A1GGPS1CHRM2CHRM4 | |
| Pyrophosphoric Acid SCHEMBL15103043 | 0.77 | TDP1 (0.56) | MVDBTN3A1GGPS1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020035058-A1 | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors | THE UNIVERSITY OF SHEFFIELD (GB) | 2002-03-21 | — | — | US | claimed |
| EP-0952834-A2 | ISOPENTENYL PYROPHOSPHATE ISOMERASE (IPI) AND/OR PRENYL TRANSFERASE INHIBITORS | The University of Sheffield (GB) | 1999-11-03 | — | — | EP | claimed |
| WO-1997043437-A2 | ISOPENTENYL PYROPHOSPHATE ISOMERASE (IPI) AND/OR PRENYL TRANSFERASE INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 1997-11-20 | — | — | WO | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3681504-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | Icagen, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055754-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| CN-101415884-B | Lather-forming tissue paper product | SCA HYGIENE PROD GMBH | 2013-02-06 | — | — | CN | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| CN-101415884-A | Lather-forming tissue paper product | SCA HYGIENE PROD GMBH (DE) | 2009-04-22 | — | — | CN | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-1141379-A1 | SCREENING FOR INHIBITORS OF TERPENOIDS BIOSYNTHESIS | Bacher, Adelbert (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000036138-A1 | SCREENING FOR INHIBITORS OF TERPENOIDS BIOSYNTHESIS | BACHER ADELBERT (DE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035058-A1 | Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors | TPI1, ALPI, PPIP5K2 | MVD 133/4885BTN3A1 4059/4885GGPS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.